Regeneron fails in study for Libtayo combo (REGN:NASDAQ)

May 16, 2026

Tumor - Cancer cells — peterschreiber.media

Regeneron (REGN) has announced a failure in a late-stage trial designed to evaluate a combination therapy involving its anti-PD-1 immunotherapy Libtayo against pembrolizumab, Merck’s (MRK) blockbuster cancer therapy marketed as Keytruda.

The Phase 3 study evaluated Regeneron’s (REGN) fianlimab

Source link

View All

Investing

For better or worse, investors are living through Trump’s stock market. Here’s why

byDylan D. DavisMay 16, 2026

[ad_1] For better or worse, investors are living through Trump’s stock market. Here's why President…

Business

Creator content takes the stage — not just for YouTube

byDylan D. DavisMay 16, 2026

[ad_1] Dwyane Wade, left, and Jesse Riedel speak onstage during the YouTube Brandcast event at…

Global

Toddlers among more than 50 schoolchildren kidnapped in Nigeria

byDylan D. DavisMay 16, 2026

[ad_1] No group has yet claimed responsibility for the attacks, which have devastated Mussa town…

Regeneron fails in study for Libtayo combo (REGN:NASDAQ)

Why Student Test Scores Have Seen a Decade-Long Drop Across the U.S.

Peloton stock rises as higher subscription prices help company drive a profitable quarter

Related Posts